Law360, New York (January 13, 2014, 6:15 PM EST) -- Everywhere you turn today the promise and potential of stem cell research is apparent. Recently, for example, researchers at the Oregon Health & Science University reported that they had successfully derived six pluripotent, embryonic stem cell lines created by somatic cell nuclear transfer ("SCNT").[1] While questions have been raised about errors in the report over duplication of figures, the experiment has nevertheless been acclaimed as a historic achievement with important clinical implications.[2] Indeed, the genetic identity of these stem cells to the patient's own cells dramatically reduces the risk of rejection should they be used in actual therapy.[3] At the same time, nagging ethical questions, such as the creation of a cloned human embryo and its possible use in reproductive human cloning, linger.[4]...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.